[Experimental study of human micro-urokinase gene therapy].
OBJECTIVE
To determine the feasibility and efficiency of gene therapy to thrombotic disease.


METHODS
The retroviral vectors containing 982 bp mUKcDNA were constructed and transfected into PA317 viral packaging cells. Recombinant retroviral particles collected from media of PA317 cells were injected into mice subcutaneous tissue, abdominal cavity and quadriceps muscle, respectively. mUK activity of plasma was measured with a synthetic substrate S-2390. Six mice were sacrificed after injection for immunofluorohistochemical staining.


RESULTS
The mUK activity in plasma was obviously increased (P < 0.01) and the expression of mUKcDNA was observed at local sites of injection by immunofluorohistochemical staining. The mUK activity was raised for 4 months.


CONCLUSIONS
The injection of recombinant viral particles containing transcriptional unit of mUKcDNA might be applied to the prevention and treatment of thrombotic disease.
Song
H
H
Laboratory of Molecular Genetics, School of Basic Medical Sciences, Shanghai Medical University.
Peng
L
L
Cui
N
N
D000818:Animals; D015316:Genetic Therapy; D005822:Genetic Vectors; D008297:Male; D051379:Mice; D011993:Recombinant Fusion Proteins / Q000235:genetics*; D012190:Retroviridae / Q000235:genetics; D014162:Transfection; D014568:Urokinase-Type Plasminogen Activator / Q000097:blood / Q000235:genetics*
D011993:Recombinant Fusion Proteins; D014568:Urokinase-Type Plasminogen Activator